Led by Codiak BioSciences CEO Douglas Williams, the CEOs criticized Belcher Pharmaceuticals, which won approval for a drug used in certain heart procedures through the FDA's 505(b)(2) pathway.
This closes out Codiak Biosciences' Series B round first announced alongside its November launch - bringing the fledgling startup's funding to $92 million.
Every wellness clinic is only as successful as the capabilities of its software. Here's where you can find the top-rated practice management solutions for med spas.
Former Biogen R&D chief Doug Williams is launching a biotech startup called Codiak BioSciences with $80 million. It is developing exosomes as a new diagnostic and therapeutic tool, beginning with pancreatic cancer.